lutetium lu-177 vipivotide tetraxetan
lutetium lu-177 vipivotide tetraxetan: sourced relationships with 1 company · 4 clinical trials tracked · 1 FDA decision.
lutetium lu-177 vipivotide tetraxetan evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could lutetium lu-177 vipivotide tetraxetan → NVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (3)
| Company | Dated record stage |
|---|---|
| Novartis AG (NVS) Reported 2022-03-23 · Current development: unknownSource Metastatic Neuroendocrine Prostate Cancer; Metastatic Castra… | Phase 4 |
| Novartis AG (NVS) Reported 2022-03-23 · Current development: unknownSource Metastatic Neuroendocrine Prostate Cancer; Metastatic Castra… | Phase 4 |
| Novartis AG (NVS) Reported 2022-03-23 · Current development: unknownSource Prostatic Neoplasms; Metastatic Castration-Resistant Prostat… | Phase 4 |
Clinical Trial Registry Records (4)
A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
Primary endpoint: Parts 1, 2C, 3 and 4: Number of Participants With Dose Limiting Toxicity (DLT)
A Prospective, Open-label, Multi-center, Single-arm, Phase II Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary endpoint: Main part: Confirmed Overall Response Rate (ORR) per Blinded Independent Central Review (BICR)
An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
Primary endpoint: Radiographic progression free survival (rPFS)
A Phase 1b Study of JNJ-78278343, Targeting Human Kallikrein 2 (KLK2) in Combination With Other Agents for Metastatic Prostate Cancer
Primary endpoint: Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with lutetium lu-177 vipivotide tetraxetan?
lutetium lu-177 vipivotide tetraxetan has dated SEC/FDA relationship records for Novartis AG.
How many clinical trials involve lutetium lu-177 vipivotide tetraxetan?
BioSniper tracks 4 clinical trials involving lutetium lu-177 vipivotide tetraxetan.
What is lutetium lu-177 vipivotide tetraxetan's latest FDA decision?
The most recent tracked FDA decision for lutetium lu-177 vipivotide tetraxetan is Approval, dated March 23, 2022.